Touchlight | DNA Is Our DNA™

Traditional DNA manufacturing relies heavily on bacterial fermentation, a process frequently limited by complexity, slow timelines, and scaling difficulties. Cell-free DNA production platforms eliminate these traditional constraints, offering a cleaner, more agile pathway to clinical and commercial deployment. By moving from sequence to material in weeks rather than months, these advanced enzymatic platforms eliminate bacterial contaminants while improving product consistency and yield across the development lifecycle.

Whether supporting mRNA production, viral vectors, or gene editing applications, scalable cell-free architectures—ranging from high-purity linear double-stranded DNA to custom circular designs—help developers overcome payload and toxicity limitations. Partnering with an established, GMP-licensed cell-free facility streamlines development and optimizes cost-of-goods profiles. Download the full asset to learn how cell-free technology can accelerate your genetic medicine programs.